

## **REMARKS**

In the Office Action, claim 66 was rejected under 35 U.S.C. §103(a) as being unpatentable over Fu et al. (U.S. Pat. No. 4,803,625) in view of Madsen et al. (U.S. Pat. No. 5,853,377), and further in view of Kapp (U.S. Publ. No. 2001/0001144 A1).

Applicant would like to thank Examiner Lena Najarian for the consideration given the inventor, Dr. Marc Abreu, and applicant's attorney at the interview of March 12, 2009. At the interview, agreement was reached with respect to claim 66 being distinguished over the prior art of record and the combination of references set forth in the Office Action. It was further agreed that, in the absence of more relevant prior art, the captioned application should be in condition for allowance.

The agreement reached was based upon a real-time monitoring of biological data to identify a particular disease. The data and the disease are compared against constantly updated medical information to prevent a life threatening event from occurring. In the absence of these features in the prior art, it was agreed that the claim, as amended, is distinguished over the prior art.


Based on the foregoing amendments and remarks, it is respectfully submitted that the claim in the present application, as it now stands, patentably

distinguish over the references cited and applied by the Examiner and is, therefore, in condition for allowance. A Notice of Allowance is in order, and such favorable action and reconsideration are respectfully requested.

However, if after reviewing the above amendments and remarks, the Examiner has any questions or comments, she is cordially invited to contact the undersigned attorneys.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:   
Jonathan L. Scherer  
Reg. No. 29,851

400 Seventh Street, N.W.  
Washington, D.C. 20004-2201  
(202) 638-6666  
Date: March 16, 2009  
JLS:ms